D Ziegler1, N Papanas, M Roden. 1. Institute for Clinical Diabetology, German Diabetes Center at the Heinrich Heine University, Leibniz Center for Diabetes Research, Düsseldorf, Germany. dan.ziegler@ddz.uni-duesseldorf.de
Abstract
AIMS: To examine the sensitivity and specificity of three cut-off points of Neuropad for the diagnosis of distal symmetric polyneuropathy and small-fibre dysfunction in patients within the first year after diagnosis of diabetes. METHODS: Neuropad results were read at 10, 15 and 20 min and evaluated for diagnostic utility in distal symmetric polyneuropathy confirmed by electrophysiology and small-fibre dysfunction in 52 patients with Type 1 diabetes and 99 patients with Type 2 diabetes. RESULTS: The prevalence of distal symmetric polyneuropathy was 15.4% in Type 1 diabetes and 43.4% in Type 2 diabetes, while that of small-fibre dysfunction was 9.6 and 31.3%, respectively. Sensitivity of Neuropad for the diagnosis of distal symmetric polyneuropathy and small-fibre dysfunction was highest in Type 1 diabetes for the 10-min threshold reaching 87.5 and 80.0%, respectively, while it was modestly high in Type 2 diabetes at 65.1 and 67.7%, respectively. Specificity in both diabetes types was modest for the 10-min threshold (44.7-48.2%). It was highest for the 20-min threshold (83.8-89.3%) at the cost of poor sensitivity at 12.5-34.9%. Negative predictive values were relatively high for all three cut-off points in both types of diabetes (64.1-97.1%) at the cost of poor positive predictive values at 12.5-71.4%. CONCLUSIONS: In patients within the first year after diagnosis of diabetes, the 10-min cut-off for Neuropad provides a relatively high sensitivity and modest specificity for distal symmetric polyneuropathy and small-fibre dysfunction, rendering the test more suitable as a screening tool than the 15- and 20-min cut-offs.
AIMS: To examine the sensitivity and specificity of three cut-off points of Neuropad for the diagnosis of distal symmetric polyneuropathy and small-fibre dysfunction in patients within the first year after diagnosis of diabetes. METHODS: Neuropad results were read at 10, 15 and 20 min and evaluated for diagnostic utility in distal symmetric polyneuropathy confirmed by electrophysiology and small-fibre dysfunction in 52 patients with Type 1 diabetes and 99 patients with Type 2 diabetes. RESULTS: The prevalence of distal symmetric polyneuropathy was 15.4% in Type 1 diabetes and 43.4% in Type 2 diabetes, while that of small-fibre dysfunction was 9.6 and 31.3%, respectively. Sensitivity of Neuropad for the diagnosis of distal symmetric polyneuropathy and small-fibre dysfunction was highest in Type 1 diabetes for the 10-min threshold reaching 87.5 and 80.0%, respectively, while it was modestly high in Type 2 diabetes at 65.1 and 67.7%, respectively. Specificity in both diabetes types was modest for the 10-min threshold (44.7-48.2%). It was highest for the 20-min threshold (83.8-89.3%) at the cost of poor sensitivity at 12.5-34.9%. Negative predictive values were relatively high for all three cut-off points in both types of diabetes (64.1-97.1%) at the cost of poor positive predictive values at 12.5-71.4%. CONCLUSIONS: In patients within the first year after diagnosis of diabetes, the 10-min cut-off for Neuropad provides a relatively high sensitivity and modest specificity for distal symmetric polyneuropathy and small-fibre dysfunction, rendering the test more suitable as a screening tool than the 15- and 20-min cut-offs.
Authors: G Ponirakis; I N Petropoulos; H Fadavi; U Alam; O Asghar; A Marshall; M Tavakoli; R A Malik Journal: Diabet Med Date: 2014-07-14 Impact factor: 4.359
Authors: N Papanas; M Demetriou; N Katsiki; K Papatheodorou; D Papazoglou; T Gioka; S Kotsiou; E Maltezos; D P Mikhailidis Journal: Exp Diabetes Res Date: 2011-09-15
Authors: Georgios Ponirakis; Hassan Fadavi; Ioannis N Petropoulos; Shazli Azmi; Maryam Ferdousi; Mohammad A Dabbah; Ahmad Kheyami; Uazman Alam; Omar Asghar; Andrew Marshall; Mitra Tavakoli; Ahmed Al-Ahmar; Saad Javed; Maria Jeziorska; Rayaz A Malik Journal: J Diabetes Res Date: 2015-05-12 Impact factor: 4.011
Authors: Julia Szendroedi; Aaruni Saxena; Katharina S Weber; Klaus Strassburger; Christian Herder; Volker Burkart; Bettina Nowotny; Andrea Icks; Oliver Kuss; Dan Ziegler; Hadi Al-Hasani; Karsten Müssig; Michael Roden Journal: Cardiovasc Diabetol Date: 2016-04-07 Impact factor: 9.951
Authors: Dan Ziegler; Karsten Winter; Alexander Strom; Andrey Zhivov; Stephan Allgeier; Nikolaos Papanas; Iris Ziegler; Jutta Brüggemann; Bernd Ringel; Sabine Peschel; Bernd Köhler; Oliver Stachs; Rudolf F Guthoff; Michael Roden Journal: PLoS One Date: 2017-03-15 Impact factor: 3.240